IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

E. R. Froesch, T. Bianda, Mehboob Hussain

Research output: Contribution to journalArticle

Abstract

Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalDiabetes and Metabolism
Volume22
Issue number4
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Insulin Resistance
Recombinant DNA
Type 2 Diabetes Mellitus
Growth Hormone
Animal Models
Technology
Therapeutics

Keywords

  • growth hormone
  • insulin resistance
  • insulin sensitivity
  • insulin-like growth factor-I
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance. / Froesch, E. R.; Bianda, T.; Hussain, Mehboob.

In: Diabetes and Metabolism, Vol. 22, No. 4, 07.1996, p. 261-267.

Research output: Contribution to journalArticle

@article{f7e35933dffa4014bf57239db62cb430,
title = "IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance",
abstract = "Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.",
keywords = "growth hormone, insulin resistance, insulin sensitivity, insulin-like growth factor-I, Type 2 diabetes mellitus",
author = "Froesch, {E. R.} and T. Bianda and Mehboob Hussain",
year = "1996",
month = "7",
language = "English (US)",
volume = "22",
pages = "261--267",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "4",

}

TY - JOUR

T1 - IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

AU - Froesch, E. R.

AU - Bianda, T.

AU - Hussain, Mehboob

PY - 1996/7

Y1 - 1996/7

N2 - Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

AB - Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

KW - growth hormone

KW - insulin resistance

KW - insulin sensitivity

KW - insulin-like growth factor-I

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=0030015606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030015606&partnerID=8YFLogxK

M3 - Article

C2 - 8767173

AN - SCOPUS:0030015606

VL - 22

SP - 261

EP - 267

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 4

ER -